A single step, centrifuge-free method to harvest bone marrow highly concentrated in mesenchymal stem cells: results of a pilot trial
- 2 November 2021
- journal article
- research article
- Published by Springer Nature in International Orthopaedics
- Vol. 46 (2) , 391-400
Abstract
Purpose The aims of the present study were: (1) to characterize the bone-marrow aspirate (BMA) obtained with a centrifuge-free process, employing a dedicated aspiration device; (2) to test the in vitro efficacy of BMA in a model of cartilage inflammation; and (3) to report the preliminary clinical results in a small cohort of patients affected by knee OA. Methods Ten patients (4 M, 6 W; mean age: 51.9 ± 9.2 yy) affected by mild to moderate unicompartmental knee OA (KL grade 2–3) were treated by intra-articular and subchondral injections of BMA obtained by a centrifuge-free process. To evaluate the effectiveness of the device in harvesting mesenchymal stem cells (MSCs), samples of the obtained BMA were tested by flow cytometry before and after subculture; BMA ability to counteract inflammation was also tested in an in vitro model of cartilage cell inflammation, evaluating the expression of MMP1, MMP3, TGFβ and TIMP-1 by real-time PCR. Patients were also evaluated up to two years’ follow-up by using: VAS for pain, IKDC-subjective and KOOS scores. Results The laboratory analysis showed that BMSCs accounted for 0.011% of BMA cells, similar to what had been expected in native bone marrow. The paracrine activity of BMA was able to reduce in vitro the catabolic response of human chondrocyte, as shown by the decrease in metalloproteases concentration and increase in anti-inflammatory mediators. Moreover, the clinical evaluation showed significant improvements in all scores adopted, with stable results up to two years. Conclusion The present data showed the effectiveness of the study device to harvest pure bone marrow with minimal peripheral blood contamination. The relevant content of MSCs resulted in the ability to counteract the catabolic cascade through a paracrine action. The clinical outcomes in patients affected by unicompartmental knee OA were encouraging in terms of pain reduction and functional improvement up to mid-term evaluation.Keywords
Funding Information
- Ministero della Salute (Ricerca Corrente)
- On foundation (Kick-off grant n. 18-054)
- Geistlich Italia
This publication has 40 references indexed in Scilit:
- Injectable Cultured Bone Marrow–Derived Mesenchymal Stem Cells in Varus Knees With Cartilage Defects Undergoing High Tibial Osteotomy: A Prospective, Randomized Controlled Clinical Trial With 2 Years' Follow‐upArthroscopy, 2013
- Mesenchymal stem cells: environmentally responsive therapeutics for regenerative medicineExperimental & Molecular Medicine, 2013
- Autologous Bone Marrow Concentrate: Review and Application of a Novel Intra-Articular Orthobiologic for Cartilage DiseaseThe Physician and Sportsmedicine, 2013
- Benefits of small volume and small syringe for bone marrow aspirations of mesenchymal stem cellsInternational Orthopaedics, 2013
- Human peripheral blood derived mesenchymal stem cells demonstrate similar characteristics and chondrogenic differentiation potential to bone marrow derived mesenchymal stem cellsJournal of Orthopaedic Research, 2011
- The MSC: An Injury DrugstoreCell Stem Cell, 2011
- Interleukin 1 receptor antagonist mediates the antiinflammatory and antifibrotic effect of mesenchymal stem cells during lung injuryProceedings of the National Academy of Sciences, 2007
- Results after microfracture of full-thickness chondral defects in different compartments in the kneeOsteoarthritis and Cartilage, 2006
- Aspiration of Osteoprogenitor Cells for Augmenting Spinal FusionJournal of Bone and Joint Surgery, 2005
- Adult bone marrow is a rich source of human mesenchymal ‘stem’ cells but umbilical cord and mobilized adult blood are notBritish Journal of Haematology, 2003